Genmab reaches milestone for Arzerra under terms of collaboration with GSK

Genmab A/S (Copenhagen:GEN) announced today it has reached a milestone for Arzerra(ofatumumab) under the terms of its collaboration with GlaxoSmithKline (GSK). A milestone payment of approximately DKK 87 million (approximately USD 16 million) was triggered by the European Commission's granting of a conditional marketing authorization for ofatumumab for the treatment of refractory chronic lymphocytic leukemia (CLL).

"This milestone marks an important achievement; the first Genmab antibody to reach the market in Europe," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab.

Ofatumumab is a novel human monoclonal antibody with a unique mode of action. It targets a unique part of the CD20 molecule encompassing an epitope in the small loop. The CD20 molecule is a key target in CLL therapy, because it is expressed in most B cell malignancies.

SOURCE Genmab A/S